anti-CD3/anti-4-1BB/anti-WT1/HLA-A02:01 trispecific T-cell engager (Concept to Medicine Biotech/Biocytogen Pharmaceuticals)

N/A

Report date: 2026/03/19 16:53:17

Base Information

Drug Nameanti-CD3/anti-4-1BB/anti-WT1/HLA-A02:01 trispecific T-cell engager (Concept to Medicine Biotech/Biocytogen Pharmaceuticals)
Drug Alias NameWT1-TOPAbody
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsTumor necrosis factor receptor superfamily member 9 modulatorsT lymphocytes stimulants +[6] 
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha ChainTumor necrosis factor receptor superfamily member 9T cell surface glycoprotein CD3 +[4] 
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesConcept To Medicine Biotech Co LtdBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsOvarian Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A